Wolfram Poenisch
0000-0002-9666-6274
4 papers found
Refreshing results…
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Successful Treatment of Patients With Newly Diagnosed/Untreated Light Chain Multiple Myeloma With a Combination of Bendamustine; Prednisone and Bortezomib (BPV)
Missing publications? Search for publications with a matching author name.